bioAffinity Technologies Inc. reported record growth in sales of its CyPath® Lung diagnostic test for lung cancer in the third quarter of 2025, marking a 95% increase over the previous quarter. Sales for the first nine months of 2025 rose 97% compared to the same period in 2024, driven by increased adoption in Veterans' hospitals and expansion in the mid-Atlantic region. The company also noted a 77% increase in the number of new patients using CyPath® Lung and improved patient compliance for at-home sample collection and return. Clinical case studies highlight the test's effectiveness in detecting early-stage lung cancer and reducing unnecessary invasive procedures.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007557170) on October 07, 2025, and is solely responsible for the information contained therein.